The 2026 ESMO Gastrointestinal Cancers Congress highlighted important developments across the spectrum of gastrointestinal oncology, from precision medicine and treatment sequencing to antibody-drug conjugates and multidisciplinary care.
Beyond individual trial results, several broader themes emerged that may influence how clinicians approach daily practice. Here are five key messages from ESMO GI 2026 that could shape multidisciplinary decision-making in the coming years.
1. Precision Oncology Is Moving Earlier
Comprehensive molecular profiling is no longer an optional step reserved for patients who have exhausted standard therapies. Instead, biomarker assessment should be integrated at diagnosis whenever feasible.
In advanced gastric and gastroesophageal junction cancers, HER2 expression, PD-L1 CPS, MSI status, and Claudin 18.2 have become important components of treatment planning. Similarly, metastatic colorectal cancer management increasingly relies on extended RAS/BRAF testing, MSI status, HER2 amplification, and the identification of rare but actionable alterations such as NTRK fusions.
Early molecular characterization allows clinicians to design an optimal therapeutic sequence rather than simply selecting the most appropriate first-line treatment.
2. Treatment Sequencing Is Becoming as Important as Treatment Selection
The traditional focus on identifying the “best first-line regimen” is gradually shifting toward constructing the most effective continuum of care.
Today’s therapeutic landscape offers an expanding number of targeted therapies, immunotherapies, antibody-drug conjugates (ADCs), and biomarker-driven strategies. Consequently, preserving patients’ performance status and anticipating subsequent treatment opportunities have become fundamental goals.
Clinical decisions increasingly require physicians to ask not only, “What is the best treatment today?” but also, “What options will remain available tomorrow?”
3. ADCs Are Reshaping the Therapeutic Landscape
One of the key themes emerging from ESMO GI 2026 was the continued expansion of antibody-drug conjugates across multiple gastrointestinal malignancies.
Following the success of trastuzumab deruxtecan in HER2-positive gastric cancer, several novel ADCs targeting HER2, TROP2, Claudin 18.2, CEACAM5, and other emerging biomarkers are being evaluated across gastrointestinal malignancies.
These agents combine highly selective targeting with potent cytotoxic payloads, with the potential to improve antitumor efficacy. As additional phase III trials mature, ADCs are expected to become an increasingly important component of routine GI oncology practice.
4. Multidisciplinary Tumor Boards Are Becoming Biology-Driven
Modern multidisciplinary discussions extend well beyond anatomical staging. Today, surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and molecular biologists increasingly integrate genomic information into therapeutic decision-making.
Questions regarding conversion therapy, metastasectomy, local ablative treatments, immunotherapy eligibility, and targeted therapy selection increasingly depend on molecular characteristics rather than imaging findings alone. The future of multidisciplinary care will therefore rely on combining clinical expertise with precision medicine.
5. Real-World Evidence Is Becoming an Essential Complement to Randomized Trials
Randomized clinical trials remain the gold standard for establishing efficacy. However, they often include highly selected patient populations that may not fully reflect routine clinical practice.
Real-world evidence has become increasingly valuable for evaluating treatment effectiveness in elderly patients, frail individuals, those with multiple comorbidities, or patients receiving later-line therapies.
Large observational cohorts and prospective registries are helping clinicians understand how innovative treatments perform outside the controlled environment of clinical trials, providing complementary evidence that supports personalized treatment decisions.
Looking Ahead
One of the broader messages from ESMO GI 2026 is that gastrointestinal oncology is entering a new phase of precision medicine. Future progress will depend not only on the development of new drugs but also on identifying the right patient, selecting the optimal treatment sequence, integrating molecular diagnostics early, and fostering multidisciplinary collaboration.
The next decade is unlikely to be defined by a single breakthrough therapy. Instead, it may be characterized by smarter therapeutic strategies built upon biomarker-guided decision-making, innovative drug platforms, and individualized patient care.
As the complexity of gastrointestinal oncology continues to increase, clinicians must evolve from simply treating diseases to orchestrating personalized treatment pathways. This shift represents one of the key messages emerging from ESMO GI 2026—and one that is already beginning to influence daily clinical practice.
Written by Maria Maddalena Laterza, MD, PhD
Find more videos on OncoDaily YouTube TV.